Catalyst Wire Dossier Catalyst Wire Dossier

Carrelizumab

camrelizumab · Jiangsu Hengrui Medicine Co., Ltd.
Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for Carrelizumab, covering 2020-08-21 to 2025-05-15. Get the full timeline:

Most recent: Clinical Trial Update: Carrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma [Phase 2]

See pricing